RESUMO
BACKGROUND: Thiopurine and allopurinol in combination are associated with clinical remission in inflammatory bowel diseases but their influence on subsequent outcomes is unclear. We compared outcomes during exposure to both thiopurines and allopurinol versus thiopurines alone. METHODS: We established a nationwide cohort of patients with inflammatory bowel diseases exposed to thiopurines ± allopurinol during 1999-2014, using registry data. Patients were followed until hospitalization, surgery, anti-TNFα, or death (as a primary composite outcome). We used Poisson regression analyses to calculate incidence rate ratios overall and stratified by calendar period (assuming the combined exposure was unintended before 2009). RESULTS: A total of 10,367 patients with inflammatory bowel diseases (Crohn's disease, n = 5484; ulcerative colitis, n = 4883) received thiopurines. Of these, 217 (2.1%) also received allopurinol. During 24,714 person years of follow-up, we observed 40 outcomes among thiopurine-allopurinol-exposed patients, and 4745 outcomes among those who were thiopurine exposed; incidence rate ratio, 1.26 (95% confidence interval, 0.92-1.73). The incidence rate ratios decreased over time: 4.88 (95% confidence interval 2.53-9.45) for 1999-2003, 2.19 (95% confidence interval, 1.17-4.09) for 2004-2008 and 0.80 (95% confidence interval, 0.52-1.23) for 2009-2014. CONCLUSION: Our nationwide inflammatory bowel disease cohort study shows that concomitant thiopurine-allopurinol is as safe to use as thiopurines alone, with a tendency towards a positive effect on clinical outcomes in recent calendar periods when combined use was intended.
Assuntos
Alopurinol/administração & dosagem , Azatioprina/administração & dosagem , Colite Ulcerativa/tratamento farmacológico , Doença de Crohn/tratamento farmacológico , Imunossupressores/administração & dosagem , Mercaptopurina/administração & dosagem , Adulto , Alopurinol/efeitos adversos , Azatioprina/efeitos adversos , Azatioprina/farmacocinética , Colite Ulcerativa/diagnóstico , Colite Ulcerativa/imunologia , Doença de Crohn/diagnóstico , Doença de Crohn/imunologia , Dinamarca , Quimioterapia Combinada/efeitos adversos , Quimioterapia Combinada/métodos , Feminino , Seguimentos , Hospitalização/estatística & dados numéricos , Humanos , Imunossupressores/efeitos adversos , Imunossupressores/farmacocinética , Masculino , Mercaptopurina/efeitos adversos , Mercaptopurina/análogos & derivados , Mercaptopurina/imunologia , Mercaptopurina/metabolismo , Mercaptopurina/farmacocinética , Pessoa de Meia-Idade , Indução de Remissão/métodos , Índice de Gravidade de Doença , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/imunologia , Tioguanina/imunologia , Tioguanina/metabolismo , Resultado do TratamentoRESUMO
BACKGROUND & AIMS: Combination thiopurine-infliximab (IFX) therapy is associated with reduced generation of antidrug antibodies (ADA) compared with IFX monotherapy. Whether past clinical response to thiopurine therapy bears an effect on ADA prevention is unknown. METHODS: This was a retrospective observational multicenter study of patients with Crohn's disease (CD) treated by IFX and thiopurines who had serial ADA measurements. Therapy was classified into past thiopurine response or its lack of, de novo combination, or IFX monotherapy. The primary endpoint was risk of ADA appearance. RESULTS: Out of 494 patients with serial ADA measurements 207 eligible patients were included in the final analysis. The 1-year cumulative risk of ADA development was similar in past thiopurine responders (19.3%) compared with past thiopurine failures (16.1%) (log rank P = .54). ADA was found in 46.6% of the monotherapy group and was significantly different compared with past thiopurine responders (P = .007) and past thiopurine failures (P = .007). The adjusted hazards for ADA development were significantly lower in past responders and past failures compared with the monotherapy group (hazard ratio, 0.47 [95% CI, 0.22-1.00] and 0.32 [95% CI, 0.11-0.93], respectively). CONCLUSIONS: Thiopurines-IFX cotherapy in patients with Crohn's disease is associated with reduced ADA formation compared with IFX monotherapy. This is probably regardless of initial thiopurine therapeutic effect.
Assuntos
Formação de Anticorpos , Doença de Crohn/tratamento farmacológico , Fatores Imunológicos/imunologia , Infliximab/imunologia , Mercaptopurina/análogos & derivados , Adolescente , Adulto , Quimioterapia Combinada , Feminino , Humanos , Fatores Imunológicos/administração & dosagem , Infliximab/administração & dosagem , Masculino , Mercaptopurina/administração & dosagem , Mercaptopurina/imunologia , Estudos Retrospectivos , Resultado do Tratamento , Adulto JovemRESUMO
Although the outcome of patients with acute lymphoblastic leukemia (ALL) has been improved continuously by chemotherapy and tyrosine kinase inhibitors, prognosis of patients with Philadelphia chromosome positive (Ph(+)) ALL still remains poor. Since further intensification of chemotherapy is limited by toxic side effects and patients with high risk of transplant-related mortality are not eligible for allogeneic stem cell transplantation new treatment strategies are urgently needed for the prevention of Ph(+) ALL relapse. There is increasing evidence that the immune system plays an essential role for the eradication or immunologic control of remaining leukemia cells. We developed several DNA-based vaccines encoding a BCR-ABL(p185) specific peptide and GM-CSF, and CD40-L, IL-27 or IL-12 and evaluated the preventive and therapeutic efficacy against a lethal challenge of syngeneic Ph(+) ALL in Balb/c mice. In vivo cell depletion assays and cytokine expression studies were performed and the efficacy of the DNA vaccine was compared with 6-mercaptopurine (6-MP) alone and the combination of the DNA vaccine and 6-MP. Preventive immunization with the vaccine BCR-ABL/GM-CSF/IL-12 and the TLR-9 agonist dSLIM induced an innate and adaptive immune response mediated by NK-cells, CD4(+) T-cells and CD8(+) T-cells leading to a survival rate of 80%. Therapeutic vaccination resulted in a significantly longer leukemia-free survival (40.7 days vs. 20.4 days) and a higher survival rate (56% vs. 10%) compared to chemotherapy with 6-MP. Remarkably, in combination with the vaccine 6-MP acted synergistically and led to 100% survival. These results demonstrate that minimal residual disease of Ph(+) ALL can be significantly better controlled by a combined treatment approach of immunotherapy and chemotherapy. This provides a rationale for improving maintenance therapy in order to reduce the relapse rate in patients with Ph(+) ALL.
Assuntos
Vacinas Anticâncer/imunologia , Mercaptopurina/farmacologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/prevenção & controle , Vacinas de DNA/imunologia , Animais , Linfócitos T CD4-Positivos/imunologia , Ligante de CD40/genética , Ligante de CD40/imunologia , Linfócitos T CD8-Positivos/imunologia , Vacinas Anticâncer/genética , Terapia Combinada , Feminino , Proteínas de Fusão bcr-abl/genética , Proteínas de Fusão bcr-abl/imunologia , Fator Estimulador de Colônias de Granulócitos e Macrófagos/genética , Fator Estimulador de Colônias de Granulócitos e Macrófagos/imunologia , Imunidade Inata , Interleucina-12/genética , Interleucina-12/imunologia , Interleucina-17/genética , Interleucina-17/imunologia , Células Matadoras Naturais/imunologia , Linfonodos/imunologia , Mercaptopurina/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Neoplasia Residual/imunologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/imunologia , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Vacinação/métodos , Vacinas de DNA/genéticaRESUMO
The antimetabolite mercaptopurine is commonly used as part of treatment regimens for acute lymphoblastic leukemia and as treatment for inflammatory bowel diseases. Adverse effects associated with mercaptopurine include myelosuppression, hepatotoxicity, and hyperpigmentation. We describe a 36-year-old man with Philadelphia chromosome-negative pre-B-cell acute lymphoblastic leukemia who experienced a serious mercaptopurine-induced hypersensitivity reaction requiring prolonged hospitalization and extensive laboratory testing and imaging. He was treated with a multiagent chemotherapy regimen. Mercaptopurine 60 mg/m(2)/day orally was started as part of his third course of chemotherapy. On day 9 of mercaptopurine therapy, the patient developed persistent fevers, skaking chills, and rigors that persisted in the absence of documented infection, consistent with drug fever. All symptoms and signs resolved after discontinuation of mercaptopurine. Use of the Naranjo adverse drug reaction probability scale indicated a probable relationship between the patient's development of fever and mercaptopurine therapy. Mercaptopurine-induced fever has been reported in patients with inflammatory bowel diseases, but this case report is the first, to our knowledge, in a patient with acute lymphoblastic leukemia. Health care professionals should be aware of the possible development of fever as a hypersensitivity reaction in patients with acute lymphoblastic leukemia treated with mercaptopurine.
Assuntos
Antimetabólitos Antineoplásicos/efeitos adversos , Antimetabólitos Antineoplásicos/imunologia , Hipersensibilidade a Drogas/etiologia , Febre/induzido quimicamente , Mercaptopurina/efeitos adversos , Mercaptopurina/imunologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Adulto , Antimetabólitos Antineoplásicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Humanos , Masculino , Mercaptopurina/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicaçõesRESUMO
PURPOSE OF REVIEW: Recognizing inflammatory bowel disease (IBD) is straightforward when alarm symptoms are present, such as bloody diarrhea and weight loss. When the presentation is subtle or atypical, physicians must determine which patients warrant evaluation for IBD. Appropriate use of noninvasive tests can help identify which patients should undergo further investigation. RECENT FINDINGS: Currently IBD serologies lack high enough sensitivity and specificity to make them useful as a screening test for distinguishing IBD from other disorders, but they may have a role in classifying subtypes of IBD. Fecal markers seem promising for helping to differentiate IBD from irritable bowl syndrome and for monitoring disease activity. Pharmacogenetically guided dosing is recommended for safe use of thiopurines but ongoing routine laboratory monitoring remains important. Thiopurine metabolite measurement can be useful but may not be needed in all cases. SUMMARY: Primary care physicians should continue to rely on routine laboratory tests and clinical suspicion to decide which patients with abdominal pain to refer to a gastroenterologist. Serology panels are not useful for IBD screening as the results may lead to unnecessary procedures. Although fecal markers do show promise as a screening test for IBD, patient resistance to providing stool samples may limit its usefulness in disease monitoring. Thiopurine metabolite levels are best used in conjunction with clinical status and routine laboratory tests to monitor clinical response and adverse events.
Assuntos
Biomarcadores/análise , Técnicas de Laboratório Clínico , Doenças Inflamatórias Intestinais/diagnóstico , Adolescente , Azatioprina/imunologia , Azatioprina/metabolismo , Criança , Pré-Escolar , Colite Ulcerativa/diagnóstico , Colite Ulcerativa/epidemiologia , Colite Ulcerativa/imunologia , Doença de Crohn/diagnóstico , Doença de Crohn/epidemiologia , Doença de Crohn/imunologia , Diagnóstico Diferencial , Fezes , Feminino , Humanos , Incidência , Doenças Inflamatórias Intestinais/epidemiologia , Doenças Inflamatórias Intestinais/imunologia , Masculino , Mercaptopurina/imunologia , Mercaptopurina/metabolismo , Pediatria/métodos , Medição de Risco , Sensibilidade e Especificidade , Índice de Gravidade de DoençaRESUMO
AIMS: To examine the allelic variation of three enzymes involved in 6-mercaptopurine/azathioprine (6-MP/AZA) metabolism and evaluate the influence of these polymorphisms on toxicity, haematological parameters and metabolite levels in patients with acute lymphoblastic leukaemia (ALL) or inflammatory bowel disease (IBD). METHODS: Clinical data and blood samples were collected from 19 ALL paediatric patients and 35 IBD patients who were receiving 6-MP/AZA therapy. All patients were screened for seven genetic polymorphisms in three enzymes involved in mercaptopurine metabolism [xanthine oxidase, inosine triphosphatase (C94-->A and IVS2+21A-->C) and thiopurine methyltransferase]. Erythrocyte and plasma metabolite concentrations were also determined. The associations between the various genotypes and myelotoxicity, haematological parameters and metabolite concentrations were determined. RESULTS: Thiopurine methyltransferase variant alleles were associated with a preferential metabolism away from 6-methylmercaptopurine nucleotides (P = 0.008 in ALL patients, P = 0.038 in IBD patients) favouring 6-thioguanine nucleotides (6-TGNs) (P = 0.021 in ALL patients). Interestingly, carriers of inosine triphosphatase IVS2+21A-->C variants among ALL and IBD patients had significantly higher concentrations of the active cytotoxic metabolites, 6-TGNs (P = 0.008 in ALL patients, P = 0.047 in IBD patients). The study confirmed the association of thiopurine methyltransferase heterozygosity with leucopenia and neutropenia in ALL patients and reported a significant association between inosine triphosphatase IVS2+21A-->C variants with thrombocytopenia (P = 0.012). CONCLUSIONS; Pharmacogenetic polymorphisms in the 6-MP pathway may help identify patients at risk for associated toxicities and may serve as a guide for dose individualization.
Assuntos
Antimetabólitos Antineoplásicos/uso terapêutico , Azatioprina/uso terapêutico , Doenças Inflamatórias Intestinais/tratamento farmacológico , Mercaptopurina/uso terapêutico , Metiltransferases/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Adolescente , Antimetabólitos Antineoplásicos/imunologia , Antimetabólitos Antineoplásicos/metabolismo , Azatioprina/imunologia , Azatioprina/metabolismo , Criança , Pré-Escolar , Feminino , Frequência do Gene/genética , Genótipo , Nucleotídeos de Guanina/genética , Nucleotídeos de Guanina/metabolismo , Humanos , Doenças Inflamatórias Intestinais/enzimologia , Masculino , Mercaptopurina/imunologia , Mercaptopurina/metabolismo , Metiltransferases/imunologia , Metiltransferases/metabolismo , Farmacogenética/métodos , Polimorfismo Genético/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/enzimologia , Tionucleotídeos/metabolismo , Resultado do TratamentoAssuntos
Doença de Crohn/tratamento farmacológico , Dessensibilização Imunológica , Hipersensibilidade a Drogas/terapia , Imunossupressores/efeitos adversos , Mercaptopurina/efeitos adversos , Toxidermias/etiologia , Toxidermias/terapia , Feminino , Humanos , Imunossupressores/imunologia , Imunossupressores/uso terapêutico , Mercaptopurina/imunologia , Mercaptopurina/uso terapêutico , Pessoa de Meia-IdadeRESUMO
Hypersensitivity reactions to 6-mercaptopurine (6-MP) or azathioprine occur during the treatment of inflammatory bowel disease (IBD), raising significant diagnostic and therapeutic challenges. Charts of 591 patient with IBD treated with 6-MP in a single center were retrospectively reviewed. All allergic reactions were recorded along with results of rechallenge, desensitization, and subsequent course of IBD. Sixteen (2.7%) allergic reactions to 6-MP were noted, with fever being the most common (14 cases). Nine of these were rechallenged with 6-MP with recurrence of the same symptoms. Azathioprine was tried in six patients and in five the same symptoms recurred. Four patients underwent successful desensitization to either 6-MP or azathioprine; all four plus another patient who tolerated direct switch to azathioprine entered long-term remission. Among the remaining 11, 5 required surgery, 2 are well on methotrexate, and 4 have chronic symptoms while being treated with other medications. If an allergic reaction to 6-MP occurs during the treatment of IBD, direct switching to azathioprine is probably not justified. Instead, desensitization to either 6-MP or azathioprine should be attempted. Patients who can tolerate these medications after previous allergic reactions have improved outcomes compared with patients who resort to other forms of treatment.
Assuntos
Hipersensibilidade/epidemiologia , Imunossupressores/efeitos adversos , Doenças Inflamatórias Intestinais/tratamento farmacológico , Mercaptopurina/efeitos adversos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Azatioprina/efeitos adversos , Azatioprina/imunologia , Dessensibilização Imunológica , Feminino , Humanos , Hipersensibilidade/complicações , Hipersensibilidade/terapia , Imunossupressores/imunologia , Doenças Inflamatórias Intestinais/complicações , Masculino , Mercaptopurina/imunologia , Pessoa de Meia-Idade , Estudos RetrospectivosAssuntos
Adamantano/análogos & derivados , Antibacterianos/imunologia , Droperidol/imunologia , Mercaptopurina/imunologia , Fito-Hemaglutininas/imunologia , Adamantano/imunologia , Adjuvantes Imunológicos , Animais , Linfócitos B/imunologia , Células Cultivadas , Cobaias , Imunossupressores , Camundongos , Camundongos Endogâmicos , Linfócitos T/imunologiaAssuntos
Antígenos , Autoantígenos , Fígado/imunologia , Alcoolismo/complicações , Animais , Doenças Autoimunes/imunologia , Inibição de Migração Celular , Hepatite/etiologia , Hepatite/imunologia , Humanos , Imunidade Celular , Leucócitos/imunologia , Fatores Inibidores da Migração de Macrófagos , Mercaptopurina/imunologiaRESUMO
In repeated injections of 6-mercaptopurine (6-MP) covalently bound with protein (6-MP-P) antibodies binding 6-MP appeared in rabbits. In such animals free 6-MP produced a lesser immunodepressive and toxic action. Injection to mice immunized with sheep erythrocytes (SE) of rabbit serum containing antibodies against 6-MP not only failed to lead to reduction of the immunodepressive action of this cytostatic, but, on the contrary, intensified the inhibition of antibody formation to the SE. Injection to mice of 6-MP bound with rabbit antiserum in vitro also enhanced its immunodepressive activity. Evidently own antibodies neutralized 6-MP, whereas foreign ones, serving as an antigen, apparently caused its accumulation in the macrophagal lymphocytic complex.